Alzamend Neuro
Quarterly Financials
| Values in thousands | 2024-07-31 | 2024-04-30 | 2024-01-31 |
|---|---|---|---|
Revenue | $0 | $76 | $0 |
Gross Profit | -12 | 63 | -12 |
EBITDA | -949 | -837 | -2,647 |
EBIT | -962 | -850 | -2,659 |
Net Income | -974 | -851 | -2,662 |
Net Change In Cash | 0 | 76 | 0 |
Free Cash Flow | -1,145 | -1,279 | -2,031 |
Cash | 1,193 | 376 | 282 |
Basic Shares | 777 | 687 | 705 |
Annual Financials
| Values in thousands | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -50 | -23 | ||
EBITDA | -9,886 | -14,847 | -12,315 | -4,950 |
EBIT | -9,937 | -14,870 | -12,319 | -9,902 |
Net Income | -9,947 | -14,878 | -12,404 | -5,203 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -8,922 | 12,134 | 1,838 | |
Free Cash Flow | -8,417 | -8,923 | -6,720 | -2,712 |
Cash | 376 | 5,140 | 14,063 | 1,929 |
Basic Shares | 676 | 650 | 593 | 484 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-10-31 | -$0.40 |
2024-07-31 | -$1.25 |
2024-04-30 | -$13.35 |
2024-01-31 | -$0.38 |
